FDA Drug Reviews Pass Muster As User Fee Deadline Looms

Law360, New York (May 1, 2012, 8:15 PM EDT) -- Supporters of the U.S. Food and Drug Administration got some ammo to use against potential opponents of the user fee reauthorization package Monday, when the U.S. Government Accountability Office reported that the FDA met nearly all of its drug review goals from 2000 to 2010.

GAO, in a report requested by Sens. Richard Burr, R-N.C., and Tom Coburn, R-Okla., found that the FDA met performance goals, outlined in past Prescription Drug User Fee Agreements, on review times for new drug and biologic applications.

The report could...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.